Trials / Unknown
UnknownNCT05448430
iTBS Can Increase Frontal Dopamine Release in PET Dopamine Imaging.
iTBS Can Increase Frontal Dopamine Release and Improve Glucose Metabolism in PET Dopamine Imaging of Patients With Schizophrenia.
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Central South University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Aim: 1. To confirm that patients with predominant negative symptoms in schizophrenia have deficits in frontal cortical dopamine release when compared with healthy control and patients with positive symptoms. 2\. Our previous study found patients with negative symptoms have more possibilities to have disorders in glucose metabolism, we wonder whether dopamine release, negative symptoms or glucose metabolism can be improved by iTBS. Study design: Case control study.
Detailed description
Eligibility Criteria: Predominant negative symptoms for Positive and Negative Syndrome Scale factor score for negative symptoms of 24 or more, and score of 4 or more on at least two of three core negative PANSS items, PANSS for positive symptoms of 19 or less, HAMD depression scale of 16 or less. Predominant positive symptoms for PANSS for positive symptoms of 20 or more. Healthy control will be recruited matching the age and sex of patient groups, Outcome Measures: Oral glucose tolerance test (OGTT), PET dopamine imaging.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Theta burst stimulation | a new paradigm of high frequency repetitive transcranial magnetic stimulation |
Timeline
- Start date
- 2022-07-15
- Primary completion
- 2024-07-01
- Completion
- 2024-07-01
- First posted
- 2022-07-07
- Last updated
- 2022-07-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05448430. Inclusion in this directory is not an endorsement.